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Abstract
Background: In low- and middle-income countries (LMIC), it is uncertain whether a “dedicated” approach to
integrating mental health care (wherein a community health worker (CHW) has the sole responsibility of
delivering mental health care) or a “designated” approach (wherein a CHW provides this service in addition to
usual responsibilities) is most effective and cost-effective. This study aims to compare the effectiveness and
cost-effectiveness of these two models of service integration relative to treatment as usual (TAU) for improving
mental health and chronic disease outcomes among patients with HIV or diabetes.
Methods/Design: This is a cluster randomised trial. We will randomise 24 primary health care facilities in the Western
Cape Province of South Africa to one of three study arms. Within each cluster, we will recruit 25 patients from HIV and 25
from diabetes services for a total sample of 1200 participants. Eligible patients will be aged 18 years or older, take
medication for HIV or diabetes, and screen positive on the Alcohol Use Disorder Identification Test for hazardous/harmful
alcohol use or depression on the Centre for Epidemiology Scale on Depression. Participants recruited in clinics assigned
to the designated or dedicated approach will receive three sessions of motivational interviewing and problem-solving
therapy, while those recruited at TAU-assigned clinics will be referred for further assessment. Participants will complete an
interviewer-administered questionnaire at baseline, and at 6 and 12 months post-enrolment to assess change in self-
reported outcomes. At these end points, we will test HIV RNA viral load for participants with HIV and HbA1c levels for
participants with diabetes. Primary outcomes are reductions in self-reported hazardous/harmful alcohol use and risk of
depression. Secondary outcomes are improvements in adherence to chronic disease treatment, biomarkers of chronic
disease outcomes, and health-related quality of life. Mixed-effect linear regression models will model the effect of the
interventions on primary and secondary outcomes. The cost-effectiveness of each approach will be assessed using
incremental cost-effectiveness ratios.
Discussion: Study findings will guide decision-making around how best to integrate mental health counselling into
chronic disease care in a LMIC setting.
Trial registration: Pan African Clinical Trials Registry, Trial registration number: ACTR201610001825403. Registered 17
October 2016.
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Background
Like many low- and middle- income countries (LMICs)
[1, 2], South Africa has a high burden of mental disorders,
with an estimated 30% of the adult population meeting
diagnostic criteria for a mental disorder at some point in
their life [3]. In South Africa, a substantial treatment gap
exists for adults with common mental disorders (CMDs),
that includes mood, anxiety and alcohol use disorders: ap-
proximately 75% of those affected never access mental
health treatment [4]. Health providers can be reluctant to
screen patients for possible CMDs because there are lim-
ited options for treatment in the public health care system
and they usually work under considerable pressure [5–7].
Publically funded mental health treatment focuses on
managing severe mental disorders within specialist psychi-
atric hospitals, with limited services being available in pri-
mary health care (PHC) services [8]. In addition, the
mental health services that are available in PHC clinics
generally focus on medication provision, with mental
health counselling rarely provided [7–9].
In South Africa, there is a public health imperative to
address this treatment gap, given evidence of the high
comorbidity of CMDs with other health conditions [10].
Untreated mental and neurological disorders are the
third largest direct contributor to the national burden of
disease and also contribute to the national burden of
disease associated with chronic communicable diseases
(such as HIV) and non-communicable disease (NCDs),
such as diabetes [10]. For example, South African studies
have shown high levels of CMD and NCD multi-
morbidity among the general population [11, 12] and pa-
tients attending PHC facilities [13]. Evidence suggests
that maladaptive coping and problem-solving skills play
a pivotal role in both CMDs and chronic diseases [14–
16]. Difficulties in accepting and disclosing a chronic
disease diagnosis may lead to depression [17]. Often al-
cohol is a (maladaptive) way of coping with having a
chronic disease [15]. As untreated depression and alco-
hol use disorders are associated with sub-optimal adher-
ence to chronic disease treatment, and consequently
increased risk of treatment failure and negative treat-
ment outcomes [18, 19], ensuring access to treatment
for these CMDs is an essential component of an effective
health system response to chronic disease.
Integrating mental health care into chronic disease
services offered in PHC clinics has been widely proposed
as a means of reducing the mental health treatment gap
and improving chronic disease outcomes in LMICs [20–
23]. Although South African health policies call for the
integration of mental health and chronic disease services
[24], shortages of mental health providers in the country
have hampered integrated service delivery [21, 25, 26].
To overcome this barrier, South Africa’s mental health
care policy framework [27] has embraced task-shifting of
basic mental health counselling from specialty mental
health providers to community health workers (CHWs).
Task-shifting basic health services to CHWs has
emerged as a strategy for addressing shortfalls in human
resources impeding the delivery of health programmes
in LMICs [28]. There is some evidence to suggest that
brief, structured counselling interventions, when task-
shifted to trained CHWs, may improve patients’ mental
health outcomes [29]. For example, three to four ses-
sions of motivational interviewing (MI) integrated with
problem-solving therapy (PST), two of the recom-
mended interventions from the World Health Organiza-
tion’s programme to reduce the mental health treatment
gap [30], improved depression and alcohol outcomes
among PHC patients in South Africa [31–34]. There is
good evidence that combining MI and cognitive-
behavioural treatments (such as PST) leads to improved
outcomes for patients with depression [35, 36], alcohol
and other substance use disorders [34], and patients with
comorbid alcohol use disorders and depression [37].
Despite this evidence, uncertainty about how to config-
ure services and resources within the PHC system to allow
for the effective integration of mental health counselling
has hindered the implementation of integrated mental
health and chronic disease services [25, 38]. On one hand,
some have shown that basic mental health counselling can
be effectively task-shifted to CHWs already working in
PHC settings [29, 39, 40], suggesting that resources avail-
able in the PHC system can be reconfigured to enable the
delivery of new programmes. In contrast, others have
argued that CHWs already in the PHC system are over-
burdened with multiple tasks and therefore unlikely to
prioritise the provision of mental health counselling (and
may lack the skills and training to be effective), noting that
additional human resources are needed for effective inte-
gration of mental health and chronic disease services [41–
43]. However, health care systems are unlikely to finance
additional resources without evidence of the cost-
effectiveness of this investment relative to other ap-
proaches to service integration [44]. To the best of our
knowledge, there has been no research comparing the
relative effectiveness and cost-effectiveness of these
approaches [29]. Addressing this knowledge gap is critical
for guiding decision-making around how to proceed with
integrating mental health into chronic disease care within
South Africa’s PHC system.
Trial objectives
The goal of this trial is to identify an effective and cost-
effective approach for integrating mental health counselling
into chronic disease care in the Western Cape province of
South Africa. The primary objective is to compare the ef-
fectiveness of a designated approach (where an existing
CHW is tasked with providing mental health counselling in
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addition to their usual responsibilities), relative to a dedi-
cated approach (where a CHW solely responsible for men-
tal health counselling is added to the chronic disease care
team), relative to treatment as usual (TAU) for reducing de-
pression and hazardous/harmful alcohol use.
Secondary objectives include comparing the effective-
ness of the interventions for improving chronic disease
outcomes (HIV1 RNA viral load for HIV and HbA1c for
diabetes), adherence to chronic disease treatment, and
health-related quality of life (HrQoL) and exploring po-
tential mediators and moderators of the effects of the in-
terventions on primary outcomes. In addition, we will
compare the cost-effectiveness of each intervention
alternative from a societal perspective.
Methods
This manuscript is in accordance with the Standard
Protocol Items: Recommended items to address in a
clinical trial protocol and related documents (SPIRIT)
guidelines. See Additional file 1 for the Standard
Protocol Items: Recommendations for clinical trial
protocol (SPIRIT) checklist.
Trial design
Project Mind is a three-arm, cluster randomised controlled
trial, with the clusters being Western Cape Department of
Health (WCDOH) PHC clinics that offer HIV and diabetes
treatment and care (see Consort diagram in Fig. 1). The
intervention will influence the staff delivering HIV and dia-
betes services within PHC clinics, thus randomisation is at
the level of the PHC clinic to avoid contamination.
Study sites: selection and randomisation
The trial will be conducted at 24 co-located HIV and dia-
betes treatment clinics in the Western Cape. For these
clinics to be included in the trial, they needed to treat large
enough numbers of patients to facilitate patient recruit-
ment and be co-located within PHC facilities. For the most
part, HIV and diabetes services are provided by separate,
vertically organised clinics co-located within the same PHC
facility; this study requirement therefore is unlikely to
introduce a selection bias. The WCDOH purposively se-
lected PHC facilities to participate in the trial. Selected fa-
cilities vary in size and the extent to which comprehensive
health services are provided in order to be broadly
Fig. 1 Consort diagram of the study design
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representative of the mix of PHC facilities available in the
province. Facilities are located in most of the health dis-
tricts in the province, with 15 being urban and 9 being
rural sites. This urban: rural ratio is reflective of the provin-
cial distribution of PHC clinics.
An independent statistician will conduct randomisa-
tion after all PHC facilities selected to participate in the
trial formally agree to participate. Randomisation will be
based on randomly generated numbers (computer
based), stratified by urban-rural status. Within each
stratum, facilities will be allocated to the three study
arms with equal probability (1:1:1 ratio). Specifically, fa-
cilities will be assigned a random number between 0 and
1 using the rand() function in Excel. Then these facilities
will be sorted in ascending order based on the random
numbers, and the first third of facilities will be assigned
to the dedicated arm, the second to the designated arm
and the last third to the TAU arm.
It is not possible to blind investigators involved in the
delivery of the intervention to group allocation. In
addition, due to the nature of the intervention, it is not
possible to blind the facilities to group allocation. Inves-
tigators will be blind to the sequence generation, and all
allocations will be concealed until the facility is assigned
to a study arm. Further, CHWs delivering the interven-
tion and outcome assessors administering patient ques-
tionnaires will function independently of each other:
CHWs will not conduct any assessments, ensuring that
these assessments remain independent from the coun-
selling sessions and assessors collecting outcome data
remain blind to the content of the counselling sessions.
Patient recruitment and study procedures
Eligible patients will be at least 18 years of age, take
antiretroviral therapy (ART) for HIV or medication for
diabetes, screen for hazardous/harmful alcohol use
(Alcohol Use Disorders Identification Test (AUDIT) score
≥ 8) or depression (Center for Epidemiology Scale on
Depression (CES-D) score ≥ 16), not be currently receiving
treatment for a mental health condition, and not be partici-
pating in another study.
During the study period, all patients presenting for
HIV or diabetes care will be asked about their use of al-
cohol in the past year and recent low mood by their
health care provider. Patients who respond positively to
one of these two questions will be referred to an assessor
for study eligibility screening. After explaining the pur-
pose of the study, the assessor will request verbal con-
sent to screen the patient for possible study inclusion. If
a patient is eligible and interested in participating, the
assessor will make an appointment for the enrolment
visit. At this visit, the assessor will re-screen the partici-
pant for study eligibility prior to obtaining informed
consent to participate in the trial. Thereafter the assessor
will administer the baseline assessment in either English,
Afrikaans or isiXhosa, the three official languages of the
Western Cape province. This computer-assisted personal
interview collects socio-demographic information as well
as information on HIV disease, adherence and treat-
ment; diabetes disease, adherence and treatment; CMDs;
patterns of health service use and associated patient
costs; self-efficacy; readiness to change; problem-solving
styles; social support and HrQoL (see Fig. 2 for a de-
scription of the measures). Next, a registered nurse will
draw up to 10 ml of venous blood to assess the partici-
pants’ HIV viral load and HbA1c levels, as appropriate.
The blood samples will be sent to a local accredited
laboratory for analysis. The assessor will then schedule
counselling appointments for participants recruited from
facilities assigned to the intervention arms. Ideally, the
first session will take place within 3 days of the enrol-
ment visit, with the remaining two sessions scheduled 5
days apart. Participants will have 6 weeks from enrol-
ment to complete these three sessions.
Irrespective of study arm, all participants will be asked to
return to the facility at 6 and 12 months’ post-enrolment to
complete a follow-up assessment. During these follow-up
visits, the assessor will re-administer the baseline assess-
ment and the nurse will draw blood samples for repeated
HIV viral load and HbA1c testing (see Fig. 2). Participants
will have 30 days from their scheduled appointment to
complete these follow-up assessments before timing out of
that particular appointment. Transport costs associated
with attending study or counselling appointments will be
reimbursed. Participants will receive grocery vouchers for
completing the baseline and follow-up assessments.
Interventions
Control: TAU arm
Participants recruited from facilities assigned to the control
arm will receive the standard package of care when a health
provider suspects a patient may have a CMD. This standard
of care involves asking patients about their mood, stressors
and their use of alcohol when patients present for HIV or
diabetes care. If a patient discloses difficulties in these areas,
the patient may be given lifestyle advice and provided with
a referral to an on-or off-site mental health nurse or social
worker for further assessment [45]. We have previously
found that the implementation of this standard of care var-
ies considerably among facilities. Consequently, we will
provide all participants recruited in TAU facilities with a re-
source guide that contains mental health and substance
abuse services within their health sub-district and a referral
to a service provider of their choice.
Interventions: “Dedicated” and “Designated” arms
Participants recruited from facilities in the dedicated and
the designated arms will receive three sessions of MI-
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PST counselling and be referred for further mental
health treatment, if needed. Each session is about 60 mi-
nutes in duration. In addition, participants will be of-
fered a telephonic booster session 8 weeks after study
enrolment. Previous studies have shown that three to
four sessions of MI-PST are feasible to implement in
PHC settings, acceptable to CHWs and service users,
(with attendance declining after three sessions), and im-
pact positively on mental health outcomes [31–33]. The
underlying theory and content of this structured coun-
selling approach, and evidence of its efficacy for redu-
cing hazardous/harmful alcohol use and symptoms of
depression have been described previously [31–34]. The
goals of MI-PST are to motivate participants to change
their risk behaviours and to improve their problem-
solving skills so they cope better with stress and life
problems that are risk factors for CMDs and poor adher-
ence to chronic disease treatment [13–15]. During the
sessions, the counsellor and the participant collaborate
to identify problems within the participant’s life, and ex-
plore one or more of these problems while the
counsellor teaches the participant a structured PST ap-
proach to resolving these problems. Each session func-
tions iteratively to build readiness to change and
problem-solving skills. All sessions have a motivational
component, an education component (in which partici-
pants are taught problem-solving skills and how to apply
them), and includes opportunities to apply newly learned
skills through exercises and take home activities. More
specifically, participants are taught steps for addressing
problems that are important and can be solved; strat-
egies for dealing with negative and intrusive worries that
are unimportant; and steps for coping with problems
that are important but cannot be solved. These activities
are contained in a patient handbook that also summa-
rises the content of the sessions.
Therefore, it is intended that participants in both inter-
vention arms will receive the same counselling
programme, but that the job scope of the person deliver-
ing the counselling will differ. In facilities assigned to the
dedicated arm, one CHW will be added to each facility
(eight in total). This CHW will be tasked with providing
the counselling programme to patients with HIV and
those with diabetes, but will have no other formal chronic
disease-related duties. If they have spare capacity, they
may assist with administrative and other tasks for the
chronic disease care team, but their priority will be the de-
livery of project MIND’s mental health counselling pack-
age. Although these CHWs will be employed as part of
the study, their salaries and conditions of employment will
match those of the CHWs in the designated arm. In the
designated arm, we will identify eight CHW (one per facil-
ity) already employed as facility-based counsellors who
will be designated to provide the counselling programme
Fig. 2 Standard Protocol Items: Recommendations for Clinical Trials
(SPIRIT) Figure: schedule of enrolment, interventions and data collection
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to patients with HIV and those with diabetes in addition
to their usual chronic disease-related counselling respon-
sibilities. Both dedicated and designated CHWs will be re-
quired to complete a time and motion tool that captures
their activities and the time spent on each activity on a
daily basis. Activities may include mental health counsel-
ling, administrative tasks, participation in supervision or
training, and other chronic disease activities, which they
will be required to specify. This will allow for an exact un-
derstanding of their daily activities to be developed.
Counsellor training and supervision
Regardless of arm, each CHW will initially receive the
equivalent of 40 h of training in understanding CMDs,
screening for hazardous/harmful alcohol use and depres-
sion, principles of basic counselling, the MI and PST
programme, referral pathways, and responding to dis-
tressed participants. Prior to the start of training, CHWs
will complete an assessment of their knowledge, atti-
tudes, beliefs and practices around counselling for
CMDs, and these will be assessed after completion of
training to evaluate the impact of training. Role-plays
and observations will assess counsellors’ proficiency in
delivering the counselling programme. Each counsellor
will receive refresher training between 2 and 3 months
after the start of the study. A psychological counsellor
will conduct regular face-to-face and virtual supervision
with the counsellors in order to review participants’ pro-
gress, provide feedback on how the quality of counsel-
ling can be improved, and allow for the prevision of
additional training if required. The number of hours
spent on training and supervision per individual CHW
will be recorded in a training and supervision log.
Treatment fidelity and monitoring
For pragmatic reasons, we will not assess the fidelity
with which standard care is delivered, although we will
collect information on whether participants were re-
ferred to mental health services and we will ask partici-
pants about the use of these services at follow-up. For
the dedicated and designated arms, we will assess treat-
ment fidelity using the five steps recommended by the
Behavioral Change Consortium’s treatment fidelity
framework [46]. To evaluate the impact of training, we
will assess changes in CHWs’ knowledge, attitudes, be-
liefs and practices around CMD counselling after com-
pletion of training. Second, we will audio-record
counselling sessions to measure treatment differentiation
(whether the CHWs delivered the intended programme
and not another programme), competency (whether the
CHWs maintained the counselling skills learned during
training), and adherence (delivery of the intervention
components as intended) [43]. We will select a random
sample of audio-recorded counselling sessions to review
for each counsellor. Third, we will assess whether the
participant understood and retained the content of treat-
ment by enquiring whether participants completed their
take home activities and whether they had any difficulty
with these assignments. Fourth, we will analyse the au-
diotapes of the counselling sessions to assess the degree
of counselling enactment, or the extent to which the
participant transferred the skills and strategies learned
during counselling to real-life problems [43]. We will re-
port on the training of the CHWs in the main trial pub-
lication, there will be a separate publication on
treatment fidelity.
Study measures
The schedule of data collection is shown in Fig. 2, the
SPIRIT Figure.
Primary outcome measures
All primary outcomes are at the level of the individual
patient and will be collected at baseline and the two
follow-up assessments.
Hazardous/harmful alcohol use as measured by the 12-
item Alcohol Use Disorders Identification Test (AUDIT)
[47]. The AUDIT has been validated for use among South
African patients utilising health care facilities [48].
Depressive symptomatology as measured by the Center
for Epidemiologic Studies Depression Scale (CES-D), a
20-item scale that measures depressive feelings and be-
haviours during the past week [49] and has been used to
measure change in symptoms of depression among PHC
patients [31, 34].
Secondary outcome measures
Biomarkers of chronic disease treatment outcomes
HbA1c levels (for diabetes) and HIV-1 RNA viral load
levels (for HIV) will measure change in risk for chronic dis-
ease treatment failure. Biologic measures will be recorded
as continuous variables and dichotomized as normal or ab-
normal using standard cut-offs (> = 7 for HbA1c and > =
1000 copies/ul for viral load).
Adherence to chronic disease treatment Three mea-
sures will assess adherence to HIV and diabetes treatment,
respectively. The AIDS Clinical Trials Group (ACTG)
adherence questionnaire assesses patients’ current medica-
tions, dosing schedule, and medication doses missed over
the past four days [50]. The Visual Analog Scale (VAS)
assesses general levels of adherence over a 30-day time-
frame [51]. For the ACTG and VAS, adherence levels will
be examined as continuous variables and dichotomised
using standard cut-off scores for adherence (e.g. > = 90%).
The third measure is the CASE Adherence Index [52].
Questions on barriers to adherence are also included.
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Health-related quality of life (HrQoL) The EuroQol 5
(EQ-5D) will assess HrQoL. The EQ-5D generates a sin-
gle index that measures how much someone’s life could
be extended and improved [53]. From this index,
quality-adjusted life years (QALY) will be estimated.
Possible mediators and moderators of outcomes
We will collect information on a variety of variables
thought to potentially mediate or moderate response to
the counselling intervention. The 25-item Social
Problem-Solving Inventory Revised-Short Form will be
used to assess problem-solving styles. This has been
adapted for use among South African populations [54].
The MOS Social Support survey will assess nature and
extent of social support [55]. We will also use the 10-
item Generalized Self-efficacy Scale to assess partici-
pants’ confidence in their ability to solve and cope with a
range of problems [56] and the Trauma History Ques-
tionnaire will examine lifetime trauma exposure [57].
We will assess other risk behaviours that may impact on
study outcomes. We will examine frequency, quantity
and chronicity of tobacco use. In addition, the 11-item
Drug Use Disorders Identification Test will assess harm-
ful patterns of illicit drug use and dependence [58]. The
10-item Kessler psychological distress scale will examine
extent of psychological distress [59].
Economic/costing measures
Full economic costs will be assessed from a societal (i.e.
provider and patient) perspective within each of the
three study arms. For the provider perspective, costs in-
clude the costs of the dedicated/designated approach,
the costs of chronic disease (HIV/diabetes) care, and the
costs of a range of referral services (e.g. referral for TB
treatment or inpatient care). While TAU does not in-
clude any counselling costs, our inclusion of chronic dis-
ease and referral costs for each of the three arms
ensures that any potential changes to a broader range of
costs is captured. Provider costs will be estimated using
a combination of ingredients and step-down methods. A
time and motion study will capture the time spent by
dedicated or designated CHWs on their daily activities.
This will enable an assessment of excess capacity (hy-
pothesized to occur in the dedicated CHWs) and econ-
omies of scope (hypothesized to occur in the designated
CHWs). Ultimately, a provider cost per patient year will
be computed for each study arm/chronic disease.
In the patient perspective, costs include travel costs,
the opportunity costs of travel and waiting times, prod-
uctivity gains or losses and out-of-pocket payments
(such as food purchased during a clinic visit, user fees
for a private hospital stay, and the costs of additional
over-the-counter medicines). Using patient question-
naires, these data will be collected for all of the health
services utilized by the patient during the month preced-
ing the interview for the baseline and follow-up assess-
ments (including additional mental health services). We
will extrapolate these data in order to calculate a patient
cost per patient year for each study arm/chronic disease.
In addition, we will collect a range of socioeconomic
and demographic data to enable an assessment of
patient costs and catastrophic expenditure by socioeco-
nomic status.
Sample size considerations
This trial is powered to detect reductions in hazardous/
harmful alcohol use and risk of depression at 12-month
follow-up. The total sample size required to assess these
outcomes is 1200 participants. Sample size calculations
are based on a cluster randomised design with two active
arms and a control arm. The sample size is based on sep-
arate analyses of diabetes and HIV clinic populations,
showing a difference between the active arms using two-
sided tests at α = 0.05 and 90% power. The statistical com-
parison will be the mean scores of the CES-D and AUDIT
at 12-month follow-up. Guided by international and local
cluster trials of depression and alcohol use among primary
care patients which found ICCs ranging between 0.025
and 0.040 [60, 61], we set the intra-class correlation at
0.030, which is reasonable for outcomes in patients from
PHC facilities. Given findings from previous MI [62, 63]
and MI-PST [34] interventions, we expect to find a three-
unit difference in AUDIT scores at follow-up between the
active arms (considered clinically significant) and a
between-person standard deviation of 6.5. For this specifi-
cation with 20 patients per cluster, eight clinics per arm
are needed (24 in total). Guided by findings of PST inter-
ventions for depression [34, 64], we anticipate a five=unit
difference in CES-D scores between the active arms (con-
sidered clinically significant) and a between-person stand-
ard deviation of 10 units. For this specification, with 20
participants per cluster, seven clinics per arm are needed
(21 in total). We will inflate the cluster size of 20 partici-
pants to 25 participants per cluster to cater for a worst-
case scenario of a 20% attrition rate. Consequently, a sam-
ple size of eight clinics per arm (24 HIV and 24 diabetes
services in total), with a cluster size of 25 participants (600
unique participants from HIV and 600 unique participants
from diabetes clinics) will meet the inference require-
ments of the trial. During our pilot phase, we recruited
participants with depression and those with hazardous/
harmful alcohol use in a 2:1 ratio. To ensure we have suffi-
cient power to detect change in alcohol outcomes during
the trial phase, we will examine the number of recruited
participants who are eligible based on their alcohol use
once we have completed recruitment in each site. If neces-
sary, we will augment the sample by recruiting additional
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participants with hazardous/harmful alcohol use until the
required number of 25 is obtained.
Data analysis
Primary analyses
With 24 clusters, individual-level analyses of trial out-
comes are possible. Mixed-effect linear regression models
will be used with clusters and participants specified as
random effects to take account of the clustering at the fa-
cility level and the repeated measures within participants.
We will create separate models for alcohol and depression.
The analysis will be intention-to-treat. For cluster RCTs,
the dropout of clusters is rare. We will consider using
multiple imputations to account for missing responses of
participants at follow-up in order to reflect the true overall
uncertainty of the estimated effect sizes. The two primary
outcomes will be ascertained at three time points for each
participant. This repeated measure feature will be used to
estimate the intervention effects and 95% confidence in-
tervals for the two primary outcomes at 12 months for
three contrasts (the contrast between the Dedicated arm
and TAU arm, the contrast between the Designated arm
and TAU, and the contrast between the two active arms
(Dedicated versus Designated), which will serve as the
main comparison). Our primary analysis of outcomes will
include adjustment for stratification variables. No adjust-
ment for multiplicity will be made since the trial outcome
will be determined by the overall significance of the group
(intervention) effect. A similar approach will be adopted
to estimate the intervention effects and 95% confidence
intervals for the secondary outcomes.
Cost-effectiveness analysis
Decision analytical models will be developed to assess
intervention costs and outcomes per patient year, from
the societal, provider and patient perspective. Discount-
ing will be considered when appropriate. Incremental
cost-effectiveness ratios will be used to compare the
relative differences between TAU and each active arm.
From the provider perspective and within each arm, the
cost per patient year will be the product of the
utilization of different service units (for example coun-
selling sessions or hospital services) and the unit cost
per service. This approach enables uncertainty to be
assessed using probabilistic sensitivity analysis on
utilization elements and caters for the inherently
skewed nature of cost data. From the patient perspec-
tive, data collected during patient assessments at base-
line and each follow-up will be analyzed using
previously established methods [65]. While cost-
effectiveness ratios will be computed for each primary
outcome measure, QALY measures will allow cost-
effectiveness results to be compared with alternative in-
terventions and for allocative efficiency to be assessed.
Moderator and mediator analyses
Moderator analysis will be performed by including the
moderator variable as an additional fixed factor or co-
variate in the regression models, and examining inter-
action effects. The following moderator analyses are
planned: (a) educational level (completed high school),
(b) readiness to change, (c) baseline AUDIT score (8–12
versus > = 13), (d) tobacco use (yes/no), (e) illicit drug
use (yes/no) and (f ) HrQoL subgroups based on the EQ-
5D scale. Participants who are less ready to change [66]
and with more severe problems [67] (as reflected in
higher baseline AUDIT scores, co-occurring tobacco use
and illicit drug use and lower QoL) could respond differ-
ently to the counselling programme compared to partici-
pants who are ready to change and have less severe
problems, respectively. We will also use multi-level
structural equation modelling to test a multi-mediation
model that assesses whether problem-solving skills, self-
efficacy and social support mediate the effect of the
intervention on outcomes and the extent to which indi-
vidual variables mediate the effect conditional on the
presence of other mediators in the model.
Ethical considerations
The South African Medical Research Council (EC 004–
2/2015), the University of Cape Town (089/2015), and
Oxford University (OxTREC 2–17) provided ethical ap-
proval for this study. The Western Cape Department of
Health also approved this study (WC2016_RP6_9). The
trial is registered with the Pan African Clinical Trials
Registry (PACTR201610001825403). Informed consent
will be obtained from all potential individual participants
prior to enrolment. Prospective participants will be in-
formed of all foreseeable risks of study involvement, that
participation is voluntary and will not affect their clinical
care, and that they may withdraw their consent without
this affecting their medical care. The consent forms are
available in English, Afrikaans and isiXhosa, the main
languages spoken in the region.
To ensure confidentiality, a unique participant identifi-
cation number will link the various study forms. We will
collect data using an electronic data collection platform
that will transmit data in real time to a central database,
enhancing data safety. The study database will be
password-protected following standard password safety
procedures. The data manager will review these data
daily for quality assurance and quality control purposes.
All data not stored electronically will be stored in
double-locked filing cabinets in designated locked of-
fices. Forms with personal identifying information will
be stored separately from case report forms. Study re-
cords will not be available to participants’ health care
providers. We will however ask participants’ consent to
share their HbA1c and HIV RNA viral load test results
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with their providers as these results may improve the
clinical care they receive.
The main risk associated with this study, shared with
other psychotherapy interventions, is initial worsening of
symptoms and risk of suicide arising from issues uncov-
ered during counselling [68]. To minimize this potential
harm, we will train staff to screen all participants who
report or display signs of distress for risk of suicide
(using the Columbia Suicide Severity rating scale [69])
and to provide referrals (based on severity of risk) to
specialised mental health services. There are also poten-
tial benefits to participation. All participants will benefit
from screening for CMDs and referral to mental health
care as appropriate. All participants will obtain more
regular chronic disease monitoring (biannual versus an-
nual) which may lead to better disease management. We
anticipate that participants in the intervention arms will
improve their mental health, adhere better to chronic
disease care and reduce their risk of chronic disease
treatment failure. Finally, on completion of the trial, all
participating clinics (regardless of allocation) will be
trained in the integrated approach found to be most ef-
fective, thus creating opportunities for improved clinical
care for patients with chronic diseases.
Trial management
A trial steering committee will be convened to provide
overall supervision of the trial, ensure its conduct is in ac-
cordance with the principles of relevant regulations, and
monitor data and trial safety. Within the trial steering
committee, a smaller data safety monitoring board will
monitor adverse and serious adverse events related and
unrelated to the trial. In addition, we will create a stake-
holder advisory group (SAG) comprising representatives
from the WCDOH, health care providers, CHWs, non-
governmental organisations and mental health and
chronic disease service users. The SAG functions to en-
sure the trial is responsive to the needs of the health sys-
tem, its partners and service constituency and to consider
how findings from the trial can guide the implementation
of mental health counselling in PHC facilities.
Discussion
In recent years, there have been several global mental
health initiatives to identify and strengthen the core ele-
ments of health systems required for integrating mental
health counselling into PHC services [21, 25] and on
implementing task-shifted mental health interventions
into primary care services [33]. Some of these initiatives
have advocated for additional staffing resources to en-
able the delivery of integrated care, while others have
used staffing resources already present in the system to
deliver these additional services. Yet, uncertainty about
which of these approaches to service integration is the
most effective and cost-effective has hampered the scale-
up of mental health counselling [25, 33]. The proposed
study will respond to this question by comparing the
relative benefits of these two common approaches to
mental health service integration on both mental and
physical health outcomes. These findings will advance
scientific knowledge in the field of mental health service
implementation by identifying a model of mental health
service integration that is effective and cost-effective.
This study has several strengths. The inclusion of chronic
disease biomarkers and patient-level economic cost data is
novel and allows for the objective demonstration of the
benefits of treating CMDs for chronic disease outcomes as
well as potential productivity gains. Another strength is the
generalizability of findings and thus potential for high im-
pact. First, we will be recruiting participants across multiple
HIV and diabetes clinics in the Western Cape. As we are
working across multiple clusters located in both rural and
urban communities, findings are likely to be generalizable
to other HIV and diabetes services in the province. Second,
chronic disease services in the Western Cape are similar to
chronic disease services in other parts of South Africa: they
are busy, under-resourced, and a significant proportion of
patients have co-occurring mental disorders [25]. Third,
this study examines mental health counselling integration
in a chronic communicable and NCD service provided by
vertically distinct services co-located within PHC clinics.
Should either approach to service integration prove more
effective and cost- effective for both HIV and diabetes ser-
vice settings, we would have identified an approach to men-
tal health service integration with potential applicability
across a range of chronic disease services. The likelihood of
this study influencing health services is good as senior offi-
cials from the WCDOH are part of the investigative team
and SAG, enhancing the likelihood that findings from this
study will be able to influence the roll out of integrated
mental health care services [70]. Further, as the
generalizability of outcomes to more than one type of
chronic disease and more than one region may influence
the implementation of integrated mental health care, find-
ings from this study have the potential to strengthen and
expand access to mental health treatment for chronic dis-
ease patients.
Fourth, findings from this study may be generalizable
to other similar LMICs. South Africa and other LMICs
are experiencing an epidemiological transition from a
disease burden dominated by communicable diseases to
one characterised by both chronic communicable and
NCDs [71]. As South Africa faces a quadruple burden of
communicable diseases, NCDs, injury and mental disor-
ders [1], it provides an ideal laboratory for health system
interventions that are potentially useful for other LMICs
experiencing similar epidemiological transitions. With
this epidemiological transition in mind, the Sustainable
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Development Goals initiative has challenged countries to
achieve a 30% reduction in premature deaths due to
NCDs by 2030 [72]. In order to achieve this goal of im-
proving NCD treatment outcomes, the delivery of NCD
services within LMICs requires strengthening. Similar to
other LMICs, South Africa’s PHC system has focused
primarily on responding to the burden associated with
communicable diseases, with NCD services being less
resourced and developed [73]. As project MIND will
generate information on the relationship between mental
health counselling, treatment adherence, and clinical
outcomes of NCD treatment outcomes, it has the poten-
tial to guide efforts to strengthen NCD services both lo-
cally and in other LMICs.
Despite these strengths, we anticipate some challenges to
trial implementation. Recruitment of individual participants
may pose challenges given the reliance on facility staff for
the initial identification of suitable patients to approach for
screening. To address this potential challenge to recruit-
ment, we have developed a PHC facility engagement
strategy that includes regular meetings with facility
management, implementation readiness workshops to build
a shared commitment to the study, joint trouble-shooting
of challenges, and regular feedback of study progress at
facility meetings. Second, retention of participants in a
three-session intervention and through the lifespan of the
study may pose some challenges. We have a comprehensive
strategy to limit attrition (including reimbursement of
transport costs) that has been used in other studies where
we have obtained more than 80% follow-up rates [74].
Third, there are other ongoing initiatives to integrate and
strengthen PHC services in the province; these other initia-
tives and contextual differences between facilities may affect
study findings. We will collect contextual information and
information on other service improvement initiatives regu-
larly from each clinic in order to account for any additional
bias. Another potential challenge relates to the quality of
counselling provided by CHWs given that CHWs may have
low levels of mental health literacy. Although the quality of
counselling has a significant influence on the proposed
outcome, in order to enhance the quality of care in both of
the intervention arms, we plan to monitor the quality and
idelity of counselling closely. We also plan to interview par-
ticipants about their experiences of counselling. Through
monitoring and participant feedback, we will learn about
the amount of training and supervision needed to develop
mental health care competencies among CHWs. This infor-
mation is likely to be relevant for the implementation of
other health programmes involving CHWs.
In summary, this study has the potential to fill an im-
portant knowledge gap regarding effective and cost-
effective approaches to integrating mental health coun-
selling into chronic disease care. Evidence generated by
this study will be of direct relevance to current efforts to
reform the public health system in SA and other LMICs
where there is a focus on expanding access to mental
health care [23–25]. To ensure that study findings are
used to expand access to mental health counselling, we
are planning to provide all participating clusters with
training on the service integration model found to be
most effective and cost-effective.
Trial status
Enrolment of PHC clusters began on 19 April and individ-
ual participants began on 17 May 2017. Recruitment is
ongoing and is expected to run through December 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 120 kb)
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